Thus, the pooled analyses provide a more
robust estimate of the treatment benefit for rolapitant
across acute, delayed, and overall phases, with more
complete responses, complete protection, no emesis, no
nausea, no clinically signifi cant nausea, and delayed
time-to-first emesis or use of rescue medication,
compared with active control